Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Cancer. 2010 Sep 28;103(7):1001-7. doi: 10.1038/sj.bjc.6605882. Epub 2010 Sep 14.

Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.

Author information

1
Department of Pharmacology and Experimental Therapeutics, School of Medicine, University of Maryland, Health Science Facility I, Room 580G, 685 West Baltimore Street, Baltimore, MD 21201, USA.

Abstract

BACKGROUND:

To determine the mechanisms associated with loss of androgen dependency and disease progression in prostate cancer (PCa), we investigated the relationship between the androgen receptor (AR) and mTOR pathways and the impact of inhibiting both pathways in androgen-dependent and castration-resistant PCa models.

EXPERIMENTAL DESIGN:

Androgen-dependent (LNCaP) and castration-resistant PCa (HP-LNCaP) cells were grown as tumours in SCID mice. Once tumours reached 500 mm(3), animals were grouped and injected subcutaneous with vehicle, our novel anti-androgen/androgen synthesis inhibitor, VN/124-1, bicalutamide, and everolimus. Tumour volumes were measured biweekly. The PSA and protein analyses were performed after completion of the treatment.

RESULTS:

The addition of everolimus to bicalutamide treatment of resistant tumours significantly reduced tumour growth rates and tumour volumes. Anti-androgen treatment also increased protein expression of multiple signal transduction pathways earlier than vehicle-treated control xenografts. VN/124-1 plus everolimus acted in concert to reduce tumour growth rates in our castration-resistant xenograft model.

CONCLUSIONS:

This study suggests that dual inhibition of AR and mTOR in castration-resistant xenograft models can restore sensitivity of tumours to anti-androgen therapy. Furthermore, after bicalutamide failure, dual inhibition with VN/124-1 and everolimus was the most effective treatment.

PMID:
20842117
PMCID:
PMC2965879
DOI:
10.1038/sj.bjc.6605882
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center